Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2013-02-11 Regulatory Filings
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Versnelde breukgenezing met CDP7851/AMG785 niet naar fase 3
Regulatory Filings Classification · 95% confidence The document is a press release dated February 11, 2013, originating from Brussels, Belgium, and is explicitly labeled as 'gereguleerde informatie' (regulated information). It announces a business decision regarding a clinical trial (stopping the Phase 3 study for CDP7851/AMG785 for accelerated fracture healing) while confirming commitment to another program (PMO). This type of announcement, detailing significant operational or strategic updates outside of routine financial reporting (like 10-K or IR), is characteristic of an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it's a specific, material, non-standard announcement. Since it is a specific, material business decision announcement, and not a full financial report, a transcript, or a management discussion, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a reporting period, but the content is purely operational/clinical. Given the nature of announcing a major strategic decision about a drug program, and the lack of specific quarterly financial figures (only a note that it doesn't affect 2012 finances), RNS is the most appropriate general regulatory category for material, non-standard news. However, many such announcements that detail operational outcomes (like trial decisions) are often categorized as Earnings Releases (ER) when they are the primary communication vehicle for the period's news, even if not strictly quarterly results. Given the structure and the focus on a major pipeline decision, it strongly resembles an Earnings Release format announcing key operational news. Since it is not a full financial report (10-K/IR) or a transcript (CT), and it is a formal announcement of material information, I will classify it as an Earnings Release (ER) as it communicates key operational performance/outlook news, which often overlaps with ERs in non-US contexts for material updates. If RNS were chosen, it would be the fallback. ER is chosen because it communicates a major development impacting future performance/outlook.
2013-02-11 Dutch
UCB: Accelerating focus on the patient
Regulatory Filings Classification · 95% confidence The document is a press release from UCB announcing a major organizational restructuring, including the creation of new business units and changes to the Executive Committee (management). While it mentions strategic growth priorities, the primary focus is on the internal reorganization and leadership changes. According to the filing definitions, announcements regarding changes in senior management or board structure fall under the 'MANG' category.
2013-02-05 English
UCB toujours plus centré sur le patient
Board/Management Information Classification · 95% confidence The document is a press release from UCB announcing a major organizational restructuring, including the creation of new business units and changes to the executive committee and management team. While it mentions financial goals, it is primarily focused on corporate governance and management changes. According to the filing definitions, announcements regarding changes in senior management or the board of directors fall under the 'MANG' category.
2013-02-05 French
UCB: steeds meer aandacht voor patiënt
Board/Management Information Classification · 95% confidence The document is a press release from UCB announcing a significant change in its organizational structure and management team. It details the creation of four new divisions, the appointment of new leadership for these divisions, and the departure of a senior executive. While it mentions financial goals, the primary purpose is to communicate corporate restructuring and management changes, which aligns perfectly with the 'Board/Management Information' category.
2013-02-05 Dutch
UCB_PSO_press release_final UK
Board/Management Information Classification · 99% confidence The document is dated February 5, 2013, is labeled as 'regulated information', and announces significant organizational restructuring, changes in management roles (Executive Committee composition), and strategic priorities. This type of announcement, detailing changes in senior management and organizational structure, directly aligns with the definition of Board/Management Information. It is not a full financial report (10-K or IR), an earnings release (ER) which focuses on results, or a proxy statement (DEF 14A) focused on remuneration. Therefore, the most appropriate classification is MANG.
2013-02-05 English
UCB_PSO_press release_final FR
Board/Management Information Classification · 99% confidence The document is dated February 5, 2013, and is explicitly labeled as "information réglementée" (regulated information). The content details significant organizational restructuring, alignment with strategic growth priorities, changes in executive leadership (including the departure of Greg Duncan and the composition of the Executive Committee), and future business outlook. This type of announcement, focusing on internal governance, management changes, and strategic direction, strongly aligns with announcements typically made via regulatory channels to inform the market about material non-public information. Since it announces changes in senior management and board structure, the most specific category is Board/Management Information (MANG). It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2013-02-05 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.